Staar Surgical CO Schedule 13D activist filings

Broadwood Partners and affiliates updated their beneficial ownership in STAAR Surgical Company to 32.6%, with Richard T. LeBuhn ceasing to be a reporting person.

STAAR Surgical Company and activist investor Broadwood Partners reach a cooperation agreement, leading to significant board changes and CEO transition.

STAAR Surgical Company announced the appointment of Christopher Min Fang Wang to its Board of Directors following a cooperation agreement with Broadwood Partners, L.P.

Yunqi Path Capital Master Fund and affiliated entities have increased their beneficial ownership in STAAR SURGICAL CO, now holding up to 6.5% of common stock.

Broadwood Partners has increased its appraisal demands for STAAR Surgical shares, opposing the proposed merger and compensation plans.

Yunqi Capital, a 5.1% shareholder, reiterates its opposition to Alcon's revised $30.75 per share offer for STAAR Surgical, citing an undervalued company and a flawed go-shop process.

Broadwood Partners and affiliated entities have increased their beneficial ownership in STAAR Surgical Company to 30.2% through recent open market purchases.

Yunqi Capital, a 5.1% shareholder, has issued an open letter to STAAR Surgical's board, calling for the termination of a proposed merger and offering a board seat for its CIO.

Yunqi Capital and its affiliates, holding 5.1% of STAAR Surgical, publicly urged the company's board to proceed with a stockholder vote on the Proposed Merger, opposing any further adjournment or rushed sales process.

Broadwood Partners, a significant shareholder in STAAR Surgical Co., has formally demanded appraisal rights for its 27.4% stake in opposition to the proposed merger.

Activist investor Broadwood Capital intends to call a special meeting to remove several STAAR Surgical directors and opposes the company's proposed merger.

Yunqi Capital and affiliates reiterate their intention to vote against STAAR Surgical's proposed merger, citing concerns over recent disclosures and urging a special stockholder meeting.

Yunqi Path Capital and affiliates, holding 5.1% of STAAR Surgical, reiterate their strong opposition to the proposed merger with Alcon, citing undervaluation and a flawed process.

Broadwood Capital, STAAR Surgical's largest shareholder, is actively opposing the proposed $28 per share acquisition by Alcon, citing inadequate price, flawed process, and board conflicts.

Yunqi Path Capital Master Fund and affiliates, holding 5.1% of STAAR Surgical, publicly announced their intention to vote against the proposed merger with Alcon, citing undervaluation and a deficient process.

A group of investors led by Broadwood Capital, holding 27.4% of STAAR Surgical, has launched a proxy solicitation to oppose the company's proposed merger with Alcon Research.

STAAR Surgical's largest shareholder, Broadwood Partners, announces its intent to vote against the proposed acquisition by Alcon Inc., citing process and valuation deficiencies.

Broadwood Capital, a significant shareholder in STAAR Surgical Company, is evaluating the proposed acquisition by Alcon and exploring alternative strategic options.

Broadwood Capital and its affiliates have further increased their beneficial ownership in STAAR Surgical Company, now holding 27.1% of outstanding common stock, through recent open market purchases.

Broadwood Capital and its affiliates have significantly increased their beneficial ownership in STAAR Surgical Company to 25.4%, asserting the company's stock is undervalued despite macroeconomic headwinds and expressing confidence in new leadership and recent corporate governance enhancements.

Broadwood Capital and its affiliates have significantly increased their beneficial ownership in STAAR Surgical Company to 24.3%, asserting the company's current valuation does not reflect its long-term potential despite recent stock price declines and operational challenges.